Skip to main content

Table 1 Baseline characteristics of study participants by treatment group

From: Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial

Characteristic

Varenicline group (N = 70)

Mean (± SD)

Placebo group (N = 70)

Mean (± SD)

p-value

Age (years)

53.8 (9.7)

51.3 (8.4)

0.0196

Years of smokinga

27.7 (7.4)

27.1 (7.3)

0.6484

Years of vapingb

2.0 (1.4)

2.1 (1.00)

0.1714

Motivation level by VAS

8.0 (7–10)c

8.5 (7–10)c

0.9611

BDI

7 (3–12.8)c

9 (5–14)c

0.2895

BAI

6 (3–13.5)c

9.5 (5–17)c

0.0151

MNWSd

9 (7–12)c

9 (6–12)c

0.8413

PSECDI

11.7 (6.2)

14.9 (7.3)

0.0283

Weight (kg)

75.2 (12.6)

79.1 (15.8)

0.1095

Height (cm)

167.8 (8.4)

168.6 (9.5)

0.5891

BMI

26.95 (4.20)

27.63 (4.04)

0.3289

SBP (mmHg)

126.9 (13.3)

127.6 (13.3)

0.7366

DBP (mmHg)

76.4 (8.1)

77.4 (10.0)

0.5092

HR (b/min)

74.4 (10.2)

77.2 (10.4)

0.1066

 

Varenicline group (N = 70)

No. (%)

Placebo group (N = 70)

No. (%)

p-value

Gender

  

0.8657

 M

36 (51.4%)

33 (47.1%)

 

 F

34 (48.6%)

37 (52.9%)

 

Marital status

  

0.7046

 Married

53 (75.7%)

55 (78.6%)

 

 Unmarried

7 (10.0%)

8 (11.4%)

 

 Divorced

5 (7.1%)

1 (1.4%)

 

 Widower

2 (2.9%)

3 (4.3%)

 

 Separated

2 (2.9%)

2 (2.9%)

 

 Cohabiting

1 (1.4%)

1 (1.4%)

 

Educational level

  

0.0415

 No education

0 (0%)

2 (2.8%)

 

 Elementary school

6 (8.6%)

8 (11.4%)

 

 Middle school

25 (35.7%)

30 (42.9%)

 

 High school

25 (35.7%)

27 (38.6%)

 

 Graduation

14 (20.0%)

3 (4.3%)

 

Cohabitant vapers

  

0.3357

 YES

32 (45.7%)

30 (42.9%)

 

 NO

38 (54.3%)

40 (57.1%)

 

Number of quit vaping attempts

  

0.2355

  > 1

41 (58.6%)

34 (48.6%)

 

 1

29 (41.4%)

36 (51.4%)

 

Main vaping devicee

  

0.7107

 Refillable tank

55 (78.6%)

53 (75.7%)

 

 Refillable pod/cartridge

9 (12.9%)

10 (14.3%)

 

 Closed pod/cartridge system

5 (7.1%)

7 (10.0%)

 

 Disposable

1 (1.4%)

0 (0.0%)

 

Main e-liquid flavorf

  

0.6909

 Tobacco

32 (45.7%)

34 (48.5%)

 

 Fruit

15 (21.4%)

17 (24.3%)

 

 Mint

6 (8.6%)

4 (5.7%)

 

 Dessert

11 (15.7%)

9 (12.9%)

 

 Mixed

6 (8.6%)

6 (8.6%)

 
  1. a Previous smoking years, prior to regular vaping. All EC users in the study were former smokers
  2. b Years of exclusive vaping. All EC users in the study were vaping daily
  3. c Median (IQR)
  4. d MNWS, measured at week-4 (varenicline, n = 58; placebo, n = 56)
  5. e A secondary device was used (15.7% and 18.6% of cases — in placebo and varenicline groups, respectively)
  6. f Alternative e-liquids were often used (45.7% and 47.1% of cases — in placebo and varenicline groups, respectively)